Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 16/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE6A | P16499 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140446 | 0.89 | PDE10A (0.44) | CASRPDE10APDE5APDE6APDE4A | |
| SCHEMBL5189813 | 0.88 | CASR (0.56) | CASRMTHFD2 | |
| SCHEMBL4151564 | 0.87 | CASR (0.50) | CASRMTHFD2 | |
| SCHEMBL4143940 | 0.86 | CASR (0.54) | CASR | |
| SCHEMBL4147993 | 0.83 | CASR (0.58) | CASR | |
| SCHEMBL4148052 | 0.81 | CASR (0.62) | CASR | |
| SCHEMBL4135270 | 0.81 | CASR (0.56) | CASR | |
| SCHEMBL3384744 | 0.78 | CASR (0.63) | CASR | |
| SCHEMBL3380700 | 0.78 | CASR (0.63) | CASR | |
| SCHEMBL4138477 | 0.77 | CASR (0.57) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | claimed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | CASR 12/4885PDE10A 754/4885PDE5A 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.